N,NЈ-bis(2-hydroxyethyl)-N-nitrosourea (BCNU) is a commonly used agent for treatment of malignant gliomas. The mechanisms of cell death and the role of Bcl-2 and Bax in a BCNU-treated rat glioma cell line were investigated. Our results indicate that apoptosis occurs only at a high concentration of BCNU with elevated levels of Bax and a reversed ratio of Bax/Bcl-2. Overexpression of Bax delivered by a herpes simplex viral vector in combination with BCNU chemotherapy enhanced the efficacy of BCNU in a rat glioma model. These findings suggest that conventional treatment with BCNU may be combined with gene therapy that delivers a bax gene into the glioma cells to achieve a high level of Bax, facilitating BCNU-induced cytotoxicity.
It affects cells in all phases of the cell cycle (non-cell cycle-specific agent), but not equally. 2 In vitro study showed that the most prevalent site of modification for BCNU is the N 7 and O 6 position of guanine and the N 3 position of cytosine. The effect of DNA cross-linkage may result from the initial chloroethylation of the O 6 position of guanine, which induces an intramolecular rearrangement that leads to guanine binding to cytosine through an ethane bridge. 3 Although BCNU has been shown to be highly effective in its genotoxicity for tumor cells in vitro 4 and has been widely used for the treatment of gliomas, 5 the process and mechanism of cell death after the DNA alkylation and cross-linking in BCNUtreated cells are not fully understood. A recent study reported that O 6 -alkylguanine DNA lesions caused by alkylating agents, including BCNU, induce apoptosis. 5 Overexpression of Bcl-2, an antiapoptotic protein, conferred partial protection from BCNU on glioma cells, suggesting that the cytotoxicity caused by BCNU may contain certain apoptotic components. 6 However, BCNU also was found to be an inhibitor of caspase 3, which plays an important role in the apoptotic cell death induced by many agents. 7 BCNU is also among the chemotherapy drugs that encounter resistance in some malignant gliomas, with the multidrug resistance nature either inherited or developed during the treatment. 8 Among the genes involved in apoptosis, bcl-2 and bax have been well characterized as important players in the process of apoptotic cell death. Both genes belong to the bcl-2 gene family, with a 20.8% identity and 43.2% similarity in their amino acid sequences; however, their functions apparently antagonize each other. 9, 10 Some evidence indicated that heterodimerization between members of the Bcl-2 family of proteins is a key event in the regulation of apoptosis. 11 The bcl-2 family consists of intracellular, membrane-associated proteins, and there is evidence that they may act by controlling mitochondrial permeability. 12, 13 Although expression of Bax alone may or may not cause cell death directly, in the presence of cell death signals such as genotoxic damage, overproduction of Bax facilitates the apoptotic process. Because Bax can form a heterodimer with Bcl-2, 11 it is speculated that the ratio of Bax to Bcl-2 may be critical in triggering cell death.
14 Several studies have indicated that the expression of Bax can be regulated by p53, 14 -16 another apoptotic gene that is activated by various genotoxic insults, including irradiation and chemotoxins. 17 This study investigated the involvement of Bcl-2 and Bax in BCNU-induced cell death on 9L glioma cells. Our results indicate that, in our model system, apoptosis occurs at a high concentration of BCNU, which involves elevated levels of Bax and a reversed ratio of Bax/Bcl-2. To prove that elevated Bax levels can enhance the efficacy of BCNU, we delivered a herpes simplex virus (HSV) vector carrying the bax gene to a rat glioma model in addition to the treatment with BCNU. Our results suggest that conventional treatment with BCNU may be enhanced by the bax gene therapy.
MATERIALS AND METHODS

Cell cultures and BCNU treatment
The rat gliosarcoma cell line 9L was a gift from the Brain Tumor Research Center (University of California, San Francisco, Calif). HSV-1 mutant d120 (ICP4-) and the supporting cell line E5 were obtained from Dr. N. DeLuca and mutant hrR3 (ICP6-) was obtained from Dr. S. Weller. Cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Life Technologies, Burlington, Ontario, Canada) and penicillin/streptomycin (Sigma, St. Louis, Mo). Cells were suspended in Dulbecco's modified Eagle's medium/10% fetal bovine serum as 10 6 cells/mL and incubated with varying concentrations of BCNU (Bristol Laboratories, Bristol-Myers Squibb of Canada, Candiac, Quebec, Canada) for 1 hour at 37°C. The BCNU was then replaced by normal medium after phosphate-buffered saline (PBS) wash.
Colony-forming assay
After the above-described treatment with BCNU, 9L cells were plated out in 12-well dishes by serial dilutions of 10 up to 1:10 6 and incubated at 37°C with 95% O 2 /5% CO 2 . On day 10, the cell cultures were stained with methylene blue for 3 minutes followed by brief wash in PBS; cell colonies were then counted. 4 
Apoptosis assay
Hoechst 33342/PI ratio analysis. At 48 hours after BCNU treatment, cells were stained with 50 g/L Hoechst 33342/ propidium iodide (PI) and then analyzed with flow cytometry. Fluorescence ratios from Hoechst 33342/PI uptake were calculated for each cell during acquisition. 18 Dead cells with a damaged plasma membrane were detected by a high PI uptake. The remaining cells were categorized into viable or apoptotic populations based on their Hoechst 33342/PI uptake ratios.
Hypodiploid DNA analysis. At 24, 48, and 72 hours after treatment with BCNU, cells were centrifuged, washed in PBS, fixed in cold (Ϫ20°C) 70% ethanol, and left at 4°C for 1 hour. Cells were washed in PBS again and treated with ribonuclease (1 mg/mL in PBS) for 60 minutes at 37°C. Cells were then washed twice in PBS and resuspended in 50 g/mL PI followed by flow cytometry analysis to generate a DNA content loghistogram. 18 Terminal deoxynucleotidyltransferase (TdT)-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining. Cells were grown on glass coverslips treated with poly(L-lysine). Treatment with BCNU was performed at 50% confluence, and cells were further incubated for 48 hours. Cells were then fixed with 4% paraformaldehyde in PBS (pH 7.4) followed by treatment with proteinase K at 20 g/mL for 15 minutes at room temperature (RT). After four 2-minute washes in PBS, samples were incubated in 2% H 2 O 2 for 5 minutes at RT to deactivate endogenous peroxidase activity before proceeding to TdT reaction. The TdT reaction was carried in TdT buffer containing 30 M Trizma base (pH 7.2), 140 M sodium cacodylate, and 1 M cobalt chloride and incubated with 0.3 U/L TdT (Life Technologies) and biotinylated deoxyuridine 5Ј-triphosphate (100 pM/25 L) for 60 minutes at RT. At the end of the incubation, the samples were washed with TB buffer (300 M sodium chloride and 30 M sodium citrate) followed by an incubation with peroxidase-labeled extra-avidin for 30 minutes at RT. The reaction product was visualized by 3,3Ј-diaminobenzidine tetrahydrochloride reaction.
Flow cytometry immunofluorescent assay
Cells were fixed with 0.5% paraformaldehyde at RT for 15 minutes followed by a treatment of 70% ethanol for 1 hour at Ϫ20°C. After several brief washes with PBS, samples were incubated overnight at 4°C with primary antibodies (Abs) against Bcl-2 (1:500; Dimension Lab, Ontario, Canada) and Bax (1:200; Upstate Biotechnology, Lake Placid, NY), respectively. After washes in PBS, the samples were exposed to secondary Abs conjugated with fluorescein isothiocyanate or tetramethylrhodamine isothiocyanate isomer R for 1 hour at RT and analyzed by flow cytometry as a log-fluorescence histogram.
Immunocytochemistry
Cells were grown on glass coverslips treated with poly(Llysine). Treatment with BCNU was performed at 50% confluence. Cells were fixed with 4% paraformaldehyde at RT for 15 minutes followed by washes in PBS. Samples were then incubated with the above-mentioned primary Abs in PBS containing 3% normal goat sera and 0.3% Triton X-100 at 4°C overnight and subsequently incubated with biotinylated antimouse or anti-rabbit immunoglobulin G (Sigma) for 1 hour at RT. This step was followed by incubation with avidin-biotin complex solution (Vector Laboratories, Burlingame, Calif) diluted 1/1000 for 1 hour at RT. The sections were washed three times, for 10 minutes each time, between incubations. The final products of the immunoreaction were visualized by reacting in a solution of 0.01% 3,3Ј-diaminobenzidine tetrahydrochloride, 0.003% H 2 O 2 , 0.05% imidazole, and 0.6% nickel ammonium sulfate in 0.05 M tris(hydroxymethyl)aminomethane-HCl buffer (pH 7.6) for several minutes at RT.
Construction of a herpes viral vector carrying bax gene
For the Bax-expressing HSV-1 vector, human Bax ␣-cDNA (a gift from Dr. S. Korsmeyer, Howard Hughes Medical Institute, Chevy Chase, Md) was constructed in an HSV-1 vector (amplicon) under a promoter from the immediate early gene of human cytomegalovirus. 19 The vector was packaged with HSV mutants: either d120, 20 which lacks the essential immediate early gene ICP4, or hrR3, which is defective in the ribonuclear reductase (ICP6) gene. 21 Expression of Bax and the titer of the bax-carrying amplicon were determined on infected E5 cells by immunocytochemistry, using a monoclonal Ab for Bax (Upstate Biotechnology). The same cells were also used for the propagation and titration of helper viruses.
For treatment with Bax viral vector (in vitro test), monolayers of 9L cells were infected with either the helper virus d120 only or with the d120-packaged Bax amplicons at a multiplicity of infection of 3 with an amplicon/helper ratio of 1:3. Cell death was examined at 24 hours postinfection. In vivo treatment of bax viral vector was carried out with an intracranial 9L glioma rat model. A total of 40 adult Wistar rats (250 -300 g) were randomly divided into four groups. A total of 50,000 9L cells were implanted stereotactically into the putamen of all animals. On day 12 postimplantation, all animals but the control group received a single dose of BCNU (8 mg/kg intraperitoneally.). Two of the three experimental groups were further given an intratumoral injection of 2.5 ϫ 10 7 plaqueforming units in 5 L of either hrR3 helper virus or the same amount of hrR3 helper virus with 8.5 ϫ 10 6 infectious particles of bax amplicon.
RESULTS
Cell viability and drug sensitivity
A colony-forming assay was performed (Fig 1A) on 9L cells treated with varying concentrations of BCNU for 1 hour, and the number of colonies formed from treated cells was counted by day 10 posttreatment. Treatment of BCNU resulted in 28.3 Ϯ 1.5% (P Ͻ .01), 2.3 Ϯ 0.1% (P Ͻ .001), and 0.12 Ϯ 0.01% (P Ͻ .001) colonies compared with untreated control cultures for 25, 50, and 100 M BCNU, respectively. When the concentration reached 500 M, no colony could be found by day 10. Interestingly, in cell viability assays that were conducted 48 hours after the treatment with the same concentrations of BCNU (Fig 1) , there was no significant difference in the number of viable cells among cultures treated with 0, 25, and 50 M BCNU. However, only 40.8 Ϯ 2.3% (P Ͻ .001) and 2.4 Ϯ 0.3% (P Ͻ .001) of cells survived at 48 hours when the concentration reached 100 and 500 M, respectively. Therefore, it was clear that either a continuous cell death or an inhibition of proliferation occurred within 10 days after the drug treatment at low concentrations. However, at high concentrations, a rather rapid cell death took place in the first 48 hours.
Apoptosis
The differences in the rates of cell death at different concentrations of BCNU suggested different mechanisms underlying the tumor inhibitory effects of the drug. To distinguish the nature of cell death induced by various concentrations of BCNU, several techniques were applied.
For flow cytometry hypodiploid cell assay (Fig 2A) , treatment with 50 M BCNU resulted in 17.5 Ϯ 5.2% of hypodiploid cells in total 9L cell culture in 48 hours, which was slightly higher than the untreated cell cultures, but there was no statistical difference. However, cultures treated with 100 and 500 M BCNU contained 50.4 Ϯ 6.1% (P Ͻ .01) and 95.5 Ϯ 2.2% (P Ͻ .001) of hypodiploid cells, respectively. Hypodiploid cellular DNA suggests DNA fragmentation that is seen in apoptotic cell death. 18 The possibility that the hypodiploid cells were due to fragmentation of DNA as a direct pharmacological effect of BCNU rather than through apoptosis could not be discounted. For this reason, other methods of confirming apoptosis were required.
A second technology, TUNEL staining, was thus used (Fig 2B) . As described in Materials and Methods, fragmented DNA was labeled "in situ" on fixed cell cultures 48 hours after the treatment with either 25 or 100 M BCNU. Numerous cells in cultures treated with 100 M BCNU were positive to the staining, whereas few cells in cultures treated with 25 M were stained. In some stained cells, fragmented nuclei were apparent (data not shown). Figure 2C shows the fluorescent microphotograph of Hoechst 33258 labeling in 9L cells treated with 25 or 100 M BCNU at 48 hours. Although untreated cells ( Fig  2C (top) ) as well as cells treated with 25 M (Fig 2C  (middle) ) BCNU showed a weak, homogenous nuclear staining of Hoechst 33258, strong and heterogeneous labeling was apparent in the nuclei of cells treated with 100 M BCNU (Fig 2C (bottom) ), indicating nuclear fragmentation and DNA condensation in those cells at a high concentration of BCNU. 
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Expression of apoptotic genes
In an attempt to investigate the possible molecular biological mechanism underlying the two different types of cell death induced by different concentrations of BCNU, the expression of Bcl-2 and Bax was examined by immunofluorescent flow cytometry and immunocytochemistry. Figure 3 shows percent changes in the levels of Bcl-2 and Bax in 9L cells when the cells were treated with either 25 or 100 M BCNU compared with the levels of untreated cells. As shown in Figure 3 , the levels of Bcl-2 increased by 31.8 Ϯ 2.7% and 71.8 Ϯ 8.8% at 25 and 100 M BCNU, respectively. However, the levels of Bax increased by 300.0 Ϯ 12.4% at 100 M BCNU, but only by 21.3 Ϯ 3.5% at 25 M BCNU, compared with the nontreated cells (P Ͻ .001, Student's t test).
Bax-induced apoptosis
To further confirm that expression of Bax induces apoptosis in glioma cells, a bax gene was transferred into the 9L cells by using a defective HSV vector. As shown in Figure 4 , infecting cells with the virally-packaged bax vector resulted in massive cell death in 24 hours, whereas infection of the cells with the non-bax-carrying virus at the same titer had no effect. This finding indicates that cell death was due to the expression of the bax gene rather than due to virus-induced cytopathology.
Bax gene therapy enhanced the efficacy of BCNU on a rat glioma model in vivo The efficacy of the viral vector expressing Bax was also demonstrated on a 9L rat glioma model in vivo. As shown in Figure 5 , 100% of the animals without any treatment died within 23 days after tumor implantation. Animals that received treatment with BCNU or BCNU in addition to the helper virus showed similar mortalities (33.3 and 37.5%, respectively). The highest survival rate (60%) was evidenced in the group of animals that received both BCNU and Bax-expressing viral amplicon. All of the surviving animals were tumor-free up until the observation period was terminated (90 days postimplantation). No abnormalities were found in the brain tissue surrounding the previous tumor site where the virus was injected.
DISCUSSION
BCNU caused two different types of growth inhibition in 9L cells. At a low concentration, the 9L cells showed a slow but persistent inhibition of growth lasting over days, which resulted in a decreased ability to form colonies. In addition, at lower concentrations of BCNU, despite little increase in the hypodiploid cell fraction, there was an accumulation of cells in G 2 phase and a decrease in the G 1 /G 0 population, suggesting mitotic arrest at these lower doses 2 (data not shown). Thus, impaired replication is a possible explanation for the decreased colonyforming efficiency observed when cells were treated with low concentrations of BCNU. At a high concentration, rapid cell death occurred within 48 hours. Flow cytometry assays for hypodiploid cells, TUNEL staining, and Hoechst 33258 nuclear morphology revealed that apoptotic cell death had taken place in the 9L cells at high concentrations of BCNU but not at low concentrations. Although the ratio of Bax to Bcl-2 was not determined in this study, immunofluorescent flow cytometry has demonstrated that the levels of Bax were remarkably increased at the high concentration of BCNU, whereas the Bcl-2 levels remained unchanged. Furthermore, expressing Bax through a herpes viral amplicon enhanced the effect of BCNU on gliomas both in vitro and in vivo.
The difference in the effects of BCNU on 9L cells at the different concentrations suggests that there may be two distinct cytotoxic mechanisms for BCNU at low and at high dosages. Although treatment with low concentrations of BCNU eventually caused growth inhibition and probably also cell death in treated 9L cells, it was not due to accumulated drug concentration, because the BCNU was only present briefly (1 hour). A significant amount of apoptotic cell death was not detected within the first 48 hours after the treatment with low concentrations of BCNU, although a small portion of cells appeared apoptotic later in the following 8 days. These results are consistent with a recent report that showed that low concentrations of BCNU inhibit caspase-3, a protease that induces apoptosis. 7 It appears that treatment with low concentrations of BCNU initiated a process that gradually but irreversibly brings the cells to death, probably through inhibiting cell proliferation. In contract, apoptosis occurred rapidly in cells treated with high concentrations of BCNU, which involves increased levels of Bax. It has been well documented that elevated levels of Bax can induce apoptosis in various types of cells.
14 Because Bcl-2, an antiapoptotic protein, may form a heterodimer with Bax, it has been further suggested that the intracellular ratio of Bax to Bcl-2 may determine survival or death for the cell after an apoptotic stimulus. Craperi et al 22 noted in their model that elevated levels of Bax do not cause cell death in the absence of an apoptotic stimulus. However, in glioma models, increased bax is associated with cell death induced by ganciclovir, 12 and overexpression of bax also may increase the sensitivity of glioma cells to cytosine arabinoside. 23 The signal transduction pathway that stimulates the levels of Bax has still not been determined. In many cells, elevated levels of p53 induce the expression of Bax. 15, 16 However, because the p53 gene is mutant in 9L cells, 24 it remains unclear which pathway is responsible for the elevated Bax in the present case.
Treatment with the bax-carrying vector using the hrR3 HSV-1 virus on the 9L glioma model showed an additional efficacy besides the effect of BCNU. This viral vector-induced efficacy is likely due to the expression of the bax gene rather than to the packaging virus itself, because the group receiving hrR3 virus only had a similar mortality to that of the BCNU only group. The latter may be due to the BCNU-induced cytotoxicity that Figure 5 . Effects of treatment with Bax-expressing viral vector on the survival of animals with intracranial 9L glioma. After tumor implantation, all of the animals were treated with BCNU except for the control group; two of the groups also received an intratumoral injection of either packaging virus hrR3 only or bax vector packaged with hrR3. At least seven animals were in each group. The survival animals were alive up to 3 months, which was the longest survival period allowed.
limited the viral lytic infection in the tumor mass. It will be interesting to investigate whether additional treatment with ganciclovir, which causes a bystander effect in the presence of hrR3, will result in any enhancement of the efficacy observed in this study. 25, 26 Clinical dosages of BCNU are often limited by toxicity to other organ systems, and the actual drug concentrations delivered to tumor sites in vivo may be considerably lower than the levels that induce the expression of Bax and apoptosis demonstrated herein. In addition, human astrocytic tumors are often deficient in p53, which further blocks the signal transduction pathway that induces expression of the Bax. Thus, bax gene transfer via a viral vector becomes a reasonable approach to shortcut the pathway. The substantial increase in the survival rate of animals treated with the Bax-expressing viral vector in addition to BCNU suggests that once apoptosis is introduced as an additional mechanism for the treatment of gliomas, facilitating BCNU-induced cytotoxicity and overcoming the drug resistance associated with high-grade malignant gliomas may be possible.
